The Mononucleosis Rapid Test is a rapid chromatographic immunoassay for the qualitative detection of 4 serologic markers of Epstein-Barr virus (EBV), two of IgM class, VCA and heterophile antibodies, and two of IgG class, VCA and EBNA, in human whole blood, serum or plasma. It is intended to be used as a screening test and as an aid in the diagnosis of infectious mononucleosis. Any reactive specimen with the Mononucleosis Rapid Test must be confirmed with alternative testing method(s) and clinical findings.

Zhejiang Orient Gene Biotech Co., Ltd specializes in the R&D, production, and sales of in vitro diagnostic products in the field of high-end medical equipment and devices.
Currently, its main products are POCT instant diagnostic reagents, which are mainly used in the detection of infectious diseases (including COVID-19 detection products), drugs of abuse, fertility, tumor marker and cardiac marker detection, among which infectious disease and drugs of abuse detection are the two core product series of the company.
The company’s sales network has been extended to more than 120 countries and regions, and its overseas sales revenue accounted for 95% in 2019. At present, the company has obtained more than 300 overseas certifications/records, and more than 70 domestic registration/record certificates.